Drug Trial News RSS Feed - Drug Trial News

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis. [More]
Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Nektar Therapeutics reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm. [More]
Auxilium Pharmaceuticals' CCH drug effective against cellulite in Phase 2a study

Auxilium Pharmaceuticals' CCH drug effective against cellulite in Phase 2a study

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum (or CCH) for the treatment of edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite. [More]
Trovagene announces results from clinical studies on urine-based diagnostic test for detection of HPV

Trovagene announces results from clinical studies on urine-based diagnostic test for detection of HPV

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that results from two clinical studies will be presented at the 29th International Papillomavirus conference for the Company's urine-based diagnostic test for the detection of high risk strains of Human Papillomavirus. [More]
Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. [More]
KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista Pharmaceuticals, an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME. [More]
Actavis reports positive results from ceftazidime-avibactam Phase III studies in cIAI patients

Actavis reports positive results from ceftazidime-avibactam Phase III studies in cIAI patients

Actavis plc today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections. [More]
iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo Therapeutics Inc., today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs. [More]
Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen (NASDAQ: AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. [More]
Study on patients with type 2 diabetes examines fracture risk with antihypertensive treatment

Study on patients with type 2 diabetes examines fracture risk with antihypertensive treatment

It's time to question the common belief that patients receiving intensive blood pressure treatment are prone to falling and breaking bones. A comprehensive study in people ages 40 to 79 with diabetes, led by Karen Margolis, MD, of HealthPartners Institute for Education and Research in the US, found no evidence supporting this belief. [More]
Neo40 nitric oxide supplement helps promote normal blood pressure

Neo40 nitric oxide supplement helps promote normal blood pressure

Nitric oxide supplementation using a Neo40 lozenge significantly helps promote normal blood pressure, as indicated by a 30-day, blinded, placebo-controlled clinical study, conducted at the California Medical Institute by renowned cardiology researcher Dr. Ernst Schwarz. [More]
Modified C. novyi-NT bacterium produces precisely targeted anti-tumor response

Modified C. novyi-NT bacterium produces precisely targeted anti-tumor response

A modified version of the Clostridium novyi (C. novyi-NT) bacterium can produce a strong and precisely targeted anti-tumor response in rats, dogs and now humans, according to a new report from Johns Hopkins Kimmel Cancer Center researchers. [More]
Clinical trial tests COXEN model in bladder cancer to find promising treatment

Clinical trial tests COXEN model in bladder cancer to find promising treatment

Imagine being able to match a cancer's genes to the best treatment. That's the promise of COXEN (CO eXpression ExtrapolatioN) - a computer program that looks at a panel of cancer genes in a patient's tumor to predict whether it will respond to chemotherapy. [More]
MicroVAX begins phase I clinical trial for proprietary cancer vaccine platform

MicroVAX begins phase I clinical trial for proprietary cancer vaccine platform

MicroVAX, LLC, a biotech company located in Manassas, Virginia announced today the commencement of a phase I clinical trial for its unique and proprietary vaccine platform that allows under the provisions of an FDA IND entry of patients with cancers of the, breast, prostate, colon, ovary and lung, that have relapsed after initial salvage therapy. [More]
Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Rigel Pharmaceuticals, Inc. today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease. [More]
Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries

Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries

Researchers at the University of California, San Diego School of Medicine have launched a clinical trial to investigate the safety of neural stem cell transplantation in patients with chronic spinal cord injuries. [More]
New report provides data relating to clinical trials on Spastic Cerebral Palsy

New report provides data relating to clinical trials on Spastic Cerebral Palsy

Reportbuyer.com has added a new market research report: Spastic Cerebral Palsy Global Clinical Trials Review, H2, 2014. [More]
New market research report provides data on Spinal Cord Injury clinical trial scenario

New market research report provides data on Spinal Cord Injury clinical trial scenario

Reportlinker.com announces that a new market research report is available in its catalogue: Spinal Cord Injury Global Clinical Trials Review, H2, 2014. [More]
Concordia subsidiary enrolls patients in Phase 2 trial to evaluate PDT with PHOTOFRIN in mesothelioma

Concordia subsidiary enrolls patients in Phase 2 trial to evaluate PDT with PHOTOFRIN in mesothelioma

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, enrolled the first patients in a randomized Phase 2 trial to evaluate Photodynamic Therapy (PDT) with PHOTOFRIN for patients with epithelioid malignant pleural mesothelioma (MPM). [More]

SCILEX completes patient enrollment to study Ztlido for treatment of postherpetic neuralgia

SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of late-stage pharmaceutical products focused on the treatment of pain, announced today that it has completed patient enrollment for the dermal safety studies and the pivotal pharmacokinetic study related to its investigational product Ztlido (lidocaine patch 1.8%), a next-generation branded lidocaine patch for the treatment of postherpetic neuralgia, also referred to as "after-shingles pain." [More]